full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
http://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for April, 2015

30
Apr

Two months removed from winning European approval for its lead drug, Italian biotech Newron Pharmaceuticals has raised $25.5 million to jump-start its pipeline assets, pushing forward with a stable of CNS candidates. …read more Source: Resurgent Newron hauls in $25.5M for its CNS pipeline     

29
Apr

Amgen’s regulatory team for talimogene laherparepvec (T-Vec) was grilled by a group of outside FDA experts who picked up on some major questions regarding the Phase III melanoma study that was used to back its new drug application. A vigorous defense of the drug, though, helped make a winning case for the therapy, which was […]

29
Apr

Amgen took its best case for its dual cancer-killing oncolytic virus/cancer vaccine talimogene laherparepvec (T-Vec) to an FDA advisory committee this morning. …read more Source: Amgen faces a critical review for T-Vec     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off